Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of$ 0.55. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 54.55%. A quarter ago, it was expected that this company would post a loss of$ 0.35 per share when it actually produced a loss of $0.38, delivering a surprise of -8.57%.Over the last four quarters, the company has ...